CalciMedica (CALC) Income from Continuing Operations (2019 - 2026)
CalciMedica's (CALC) quarterly Income from Continuing Operations came in at 5930000.0 in Q1 2026, up 14.6% YoY from 5174405.63 in Q1 2025, and down 25.9% on a QoQ basis from 4710000.0 in Q4 2025.
CalciMedica (CALC) Income from Continuing Operations (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 8 years of Income from Continuing Operations data on file, last reported at 5930000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 14.6% year-over-year to 5930000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26299000.0 (up 3.68% YoY) and the FY2025 annual result came in at 115772000.0, down 2.76% from the prior year.
- Income from Continuing Operations declined to 5930000.0 in Q1 2026, from 4710000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2896000.0 in Q4 2022 to a low of 22711000.0 in Q1 2023.
- A 5-year average of 6699000.0 and a median of 6172000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations slumped 431.13% — and 2024, when it surged 71.13%.
- Tracing CALC's Income from Continuing Operations over 5 years: stood at 2896000.0 in 2022, then slumped by 51.76% to 4395000.0 in 2023, then tumbled by 40.43% to 6172000.0 in 2024, then grew by 23.69% to 4710000.0 in 2025, then slipped by 25.9% to 5930000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 5930000.0 (Q1 2026), 4710000.0 (Q4 2025), and 8714000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - | -4.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.34 Mn |
| Mar 31, 2026 | -5.93 Mn |
| Dec 31, 2025 | -4.71 Mn |
| Sep 30, 2025 | -8.71 Mn |
| Jun 30, 2025 | -6.95 Mn |
| Mar 31, 2025 | -6.94 Mn |
| Dec 31, 2024 | -6.17 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Jun 30, 2024 | -7.17 Mn |
| Mar 31, 2024 | -6.56 Mn |
| Dec 31, 2023 | -4.40 Mn |
| Sep 30, 2023 | -4.87 Mn |
| Jun 30, 2023 | -7.21 Mn |
| Mar 31, 2023 | -22.71 Mn |
| Dec 31, 2022 | -2.90 Mn |
| Sep 30, 2022 | -3.43 Mn |
| Jun 30, 2022 | -3.94 Mn |
| Mar 31, 2022 | -4.28 Mn |
| Dec 31, 2021 | -8.72 Mn |
| Sep 30, 2021 | -8.52 Mn |